GO:0038147 C-X-C motif chemokine 12 receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038147 describes the molecular function of receptors that bind CXCL12 (also known as SDF-1) and transmit a signal across the membrane to change cell behavior.
• The two principal receptors carrying this activity are CXCR4 and CXCR7 (ACKR3), which differ in signaling mode and downstream effects.
• CXCL12 receptor activity controls cell migration, survival, proliferation, and epithelial-mesenchymal transition in development and disease.
• Dysregulated CXCL12/CXCR4/CXCR7 signaling is implicated in cancer growth, metastasis, tumor microenvironment remodeling, and immunodeficiency such as WHIM syndrome.
• The axis is a major drug target, with antagonists, partial agonists, and biologics under development for oncology and immune disorders.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of CXCL12 receptor function in relevant cell types.
Description
C-X-C motif chemokine 12 receptor activity (GO:0038147) is a molecular function defined as the binding of the chemokine CXCL12 and the transmission of a signal across the membrane to initiate a change in cell activity. This activity is central to how cells interpret positional and survival cues in development, immunity, and cancer. The chemokine CXCL12, also called stromal cell-derived factor-1 (SDF-1), is a homeostatic chemokine that directs cell trafficking and tissue organization. Two receptors, CXCR4 and CXCR7 (also known as ACKR3), are the main proteins that carry this activity, and they engage distinct downstream pathways. Researchers study GO:0038147 because it sits at the interface of normal physiology and multiple diseases. CXCL12 signaling through CXCR4 is a classic chemokine axis controlling leukocyte trafficking, hematopoietic stem cell retention, and organ development. CXCR7, an atypical chemokine receptor, also binds CXCL12 and modulates its availability and signaling, often promoting survival and migration in tumor cells. The axis has been linked to tumor growth, metastasis, and immune evasion across breast, prostate, and esophageal cancers. From a therapeutic standpoint, the CXCL12 receptor axis is one of the most actively pursued chemokine targets. Small-molecule antagonists, modified chemokines, and antibodies have been developed to block CXCR4 or CXCR7, and some show partial agonist activity that complicates their pharmacology. Understanding the precise molecular function of GO:0038147 is therefore essential for interpreting drug effects and designing better inhibitors. This article summarizes the definition, mechanism, key genes, disease links, and research methods for GO:0038147, based on QuickGO annotation and verified PubMed literature.
C-X-C motif chemokine 12 receptor activity At A Glance
| GO ID | GO:0038147 |
|---|---|
| GO term | C-X-C motif chemokine 12 receptor activity |
| Ontology | molecular_function |
| Definition | Combining with CXCL12 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| Synonyms | CXCL12 receptor activity; CXCR4; CXCR7; SDF-1 receptor activity; stromal cell-derived factor-1 receptor activity |
| Major function | CXCL12 binding and signal transduction across the plasma membrane |
| Ligand | C-X-C motif chemokine 12 (CXCL12/SDF-1) |
| Primary receptors | CXCR4 (canonical G-protein-coupled receptor) and CXCR7/ACKR3 (atypical chemokine receptor) |
| Related processes | Cell migration, survival, proliferation, epithelial-mesenchymal transition, immune cell trafficking |
What Is GO:0038147?
GO:0038147, C-X-C motif chemokine 12 receptor activity, is defined as combining with the C-X-C motif chemokine 12 (CXCL12) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. In practical terms, it is the receptor-side function that converts extracellular CXCL12 binding into intracellular signals. The activity is associated with CXCR4 and CXCR7 (ACKR3), and synonyms include CXCL12 receptor activity, CXCR4, CXCR7, SDF-1 receptor activity, and stromal cell-derived factor-1 receptor activity.
Why Is C-X-C motif chemokine 12 receptor activity Important in Cell Biology?
GO:0038147 is important because CXCL12 receptor activity governs fundamental cell behaviors such as directed migration, survival, and proliferation, and its dysregulation contributes to cancer progression, immune disorders, and altered tissue repair. The axis is also a validated drug target, with multiple antagonists and biologics in clinical or preclinical development, making a precise understanding of receptor function essential for pharmacology and therapeutic design.
• Controls directed cell migration and homing of hematopoietic and immune cells.
• Regulates survival and proliferation signals in normal and malignant cells.
• Promotes epithelial-mesenchymal transition and metastasis in solid tumors.
• Shapes the tumor microenvironment by recruiting and reprogramming stromal and immune cells.
• Is mutated or dysregulated in immunodeficiency such as WHIM syndrome.
• Serves as a target for small-molecule antagonists and modified chemokines in oncology.
• Modulates CXCL12 availability through CXCR7-mediated scavenging.
• Influences castration-resistant prostate cancer progression and metastasis.
• Is studied with CRISPR knockout and knock-in models to establish causality.
• Provides a paradigm for understanding atypical chemokine receptor biology.
What Happens During C-X-C motif chemokine 12 receptor activity?
CXCL12 binding and receptor engagement
In simple terms: CXCL12 docks onto its receptor like a key in a lock.
The activity begins when the chemokine CXCL12 binds to the extracellular portion of its receptor, primarily CXCR4 or CXCR7. CXCL12 is a homeostatic chemokine with high affinity for both receptors, and binding is the first step that transmits information across the membrane. The interaction is highly specific and is the defining event of GO:0038147.
Conformational change and G-protein activation
In simple terms: The receptor changes shape and switches on signaling proteins inside the cell.
For CXCR4, ligand binding induces a conformational change that activates heterotrimeric G-proteins, leading to downstream signaling cascades. This canonical G-protein-coupled mechanism is the core of signal transmission for GO:0038147. CXCR7, by contrast, is an atypical chemokine receptor that can bind CXCL12 without coupling to G-proteins in the same way, instead acting as a scavenger or signaling modulator.
Downstream signaling and cellular responses
In simple terms: Signals inside the cell tell it to move, survive, or divide.
Activated CXCL12 receptors trigger multiple pathways, including PI3K/AKT, MAPK, and JAK/STAT, which collectively regulate migration, survival, proliferation, and gene expression. In esophageal cancer, CXCL12/CXCR7 signaling activates STAT3 to promote epithelial-mesenchymal transition and metastasis. These downstream events convert receptor activity into measurable changes in cell behavior.
Receptor internalization and scavenging
In simple terms: The receptor can pull CXCL12 inside the cell to control how much signal is available.
CXCR7 is known to internalize CXCL12 and act as a scavenger, shaping the local chemokine gradient and indirectly influencing CXCR4 signaling. This regulatory layer is part of the broader function of GO:0038147 and helps explain why CXCR7 can both promote and modulate CXCL12-dependent responses.
Key Genes Involved in GO:0038147 C-X-C motif chemokine 12 receptor activity
The following genes and proteins are directly involved in CXCL12 receptor activity and its downstream biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXCL12 | Ligand for CXCR4 and CXCR7 | Central to chemokine gradient and receptor activation |
| CXCR4 | Canonical G-protein-coupled receptor for CXCL12 | Mediates migration, survival, and metastasis |
| CXCR7 (ACKR3) | Atypical chemokine receptor for CXCL12 | Scavenges CXCL12 and promotes tumor growth |
| STAT3 | Transcription factor downstream of CXCR7 | Drives EMT and metastasis in esophageal cancer |
| PIK3CA | PI3K subunit in AKT signaling | Survival signaling downstream of CXCR4 |
| AKT1 | Serine/threonine kinase | Promotes survival and proliferation |
| MAPK1 | ERK2 kinase | Migration and proliferation signaling |
| MAPK3 | ERK1 kinase | Migration and proliferation signaling |
| JAK2 | Janus kinase | Cytokine-like signaling downstream of CXCR4 |
| Tpl2 (MAP3K8) | Kinase linked to prostate cancer progression | Modulates CXCL12 axis in castration-resistant prostate cancer |
| CXCR7 in breast cancer | Regulates tumor microenvironment | Promotes growth and metastasis |
| CXCR4 in WHIM syndrome | Gain-of-function mutations | Cause immunodeficiency |
| α1-adrenergic receptors | Off-target interactions with CXCR4 | Partial agonist activity of antagonists |
| CXCL12 in tumor immunotherapy | Target for immune modulation | Blocking axis enhances anti-tumor immunity |
| CXCL12 in tumor microenvironment | Stromal signaling | Supports tumor growth and immune evasion |
How Is C-X-C motif chemokine 12 receptor activity Regulated?
CXCL12 receptor activity is regulated at multiple levels. Receptor expression levels of CXCR4 and CXCR7 are controlled by transcription factors and cytokines in the tumor microenvironment. CXCR7 acts as a scavenger to modulate local CXCL12 availability, thereby indirectly regulating CXCR4 activation. Post-translational modifications, including phosphorylation and ubiquitination, control receptor internalization and desensitization. In disease contexts, gain-of-function mutations in CXCR4, as seen in WHIM syndrome, lead to prolonged signaling and immunodeficiency. Pharmacological agents can act as antagonists or partial agonists, further tuning receptor output.
C-X-C motif chemokine 12 receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXCR4 | WHIM syndrome | Knock-in of gain-of-function mutation in hematopoietic cells |
| CXCR7 | Breast cancer metastasis | Knockout or overexpression in breast cancer cell lines |
| CXCL12 | Esophageal cancer EMT | Knockdown or overexpression in esophageal cancer cells |
| Tpl2 | Castration-resistant prostate cancer | Knockout in prostate cancer models |
| CXCR4 | Tumor immunotherapy | Knockout in syngeneic tumor models |
Cancer growth and metastasis
CXCL12 receptor activity promotes tumor progression through multiple mechanisms. In breast cancer, CXCL12/CXCR7 signaling regulates tumor growth and metastasis by modulating the tumor microenvironment. In esophageal cancer, CXCL12/CXCR7 activates STAT3 to drive epithelial-mesenchymal transition and metastasis. In prostate cancer, Tpl2 induces castration-resistant progression and metastasis, with links to the CXCL12 axis. Targeting CXCL12/CXCR4 is being explored in tumor immunotherapy.
Immunodeficiency and WHIM syndrome
WHIM syndrome is caused by gain-of-function mutations in CXCR4, leading to impaired immune cell trafficking and adaptive immunodeficiency. This highlights the importance of precise regulation of GO:0038147 for normal immune function.
Tumor microenvironment and immune evasion
CXCL12 signaling in the tumor microenvironment recruits suppressive immune cells and promotes angiogenesis, contributing to immune evasion. Blocking this axis can enhance anti-tumor immunity and is a focus of therapeutic development.
From C-X-C motif chemokine 12 receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CXCR4 loss impair cell migration? | CXCR4 knockout cell line |
| Does a WHIM-associated mutation alter signaling? | CXCR4 point-mutation knock-in |
| Does CXCR7 scavenging affect CXCL12 gradients? | CXCR7 knockout or tagged knock-in |
| Does CXCL12 overexpression promote tumor growth? | CXCL12 overexpression model |
| Does STAT3 mediate CXCR7-induced EMT? | STAT3 knockout in cancer cells |
| Can receptor internalization be tracked? | Tagged knock-in of CXCR4 or CXCR7 |
How to Study the C-X-C motif chemokine 12 receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of receptor function | CXCR4 or CXCR7 knockout cells |
| CRISPR knock-in | Specific mutations | WHIM syndrome mutations |
| RNA-seq | Transcriptional changes | CXCL12-stimulated cells |
| Phosphoproteomics | Signaling events | Receptor activation |
| Transwell migration | Cell migration | Chemotaxis assays |
| Live-cell imaging | Receptor internalization | CXCR7 scavenging |
| Flow cytometry | Surface receptor levels | CXCR4 expression |
| ELISA | CXCL12 levels | Tumor microenvironment |
CRISPR knockout and knock-in
CRISPR-Cas9 can generate CXCR4 or CXCR7 knockout cell lines to test loss of function, or knock-in specific mutations such as WHIM-associated CXCR4 variants to study gain of function. These models provide causal evidence for the role of GO:0038147 in cell behavior.
RNA-seq and transcriptomics
RNA sequencing after CXCL12 stimulation or receptor knockout reveals downstream transcriptional programs, including STAT3 target genes and EMT markers. This helps map the signaling network downstream of GO:0038147.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can identify phosphorylation events and protein interactions following receptor activation, providing a global view of signaling.
Imaging and migration assays
Live-cell imaging and transwell migration assays measure chemotaxis and receptor internalization, directly linking GO:0038147 to cell movement.
How CRISPR Can Be Used to Study GO:0038147 C-X-C motif chemokine 12 receptor activity
Knockout
CRISPR knockout of CXCR4 or CXCR7 abolishes CXCL12 receptor activity, allowing researchers to test whether specific cellular responses depend on this function. Knockout models are essential for distinguishing receptor-specific effects from off-target signals.
Point Mutation
Point mutations can mimic disease-associated variants, such as gain-of-function CXCR4 mutations in WHIM syndrome, to study altered signaling and trafficking. These models provide insight into how single amino acid changes affect GO:0038147.
Knock-in
Knock-in of tagged receptors (e.g., fluorescent or epitope tags) enables real-time tracking of receptor localization, internalization, and interaction with CXCL12. This is valuable for understanding scavenging by CXCR7.
Overexpression
Overexpression of CXCL12 or its receptors can model tumor microenvironment conditions where the axis is hyperactive, driving proliferation and metastasis. Such models are useful for testing antagonists.
How EDITGENE Supports C-X-C motif chemokine 12 receptor activity Research
Researchers studying C-X-C motif chemokine 12 receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, migration, or disease progression. EDITGENE provides CRISPR-based tools to create precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for C-X-C motif chemokine 12 receptor activity research.
Frequently Asked Questions About C-X-C motif chemokine 12 receptor activity
What is C-X-C motif chemokine 12 receptor activity?
It is the molecular function defined by GO:0038147, where a receptor binds CXCL12 and transmits a signal across the membrane to change cell activity.
What genes are involved in C-X-C motif chemokine 12 receptor activity?
The main genes are CXCL12 (ligand), CXCR4, and CXCR7 (ACKR3), along with downstream effectors like STAT3.
What is the role of CXCR4 in CXCL12 signaling?
CXCR4 is the canonical G-protein-coupled receptor that mediates migration, survival, and proliferation upon CXCL12 binding.
How does CXCR7 differ from CXCR4?
CXCR7 is an atypical chemokine receptor that can scavenge CXCL12 and signal through non-G-protein pathways, often promoting tumor growth.
What diseases are linked to CXCL12 receptor activity?
It is linked to cancer metastasis, WHIM syndrome, and tumor immune evasion.
How can CRISPR be used to study CXCL12 receptors?
CRISPR knockout, knock-in, and overexpression models allow causal testing of receptor function in cells.
What is WHIM syndrome?
WHIM syndrome is an immunodeficiency caused by gain-of-function mutations in CXCR4, affecting CXCL12 receptor activity.
Is CXCL12 receptor activity a drug target?
Yes, antagonists and partial agonists targeting CXCR4 and CXCR7 are under development for cancer and immune disorders.
What methods measure CXCL12 receptor activity?
Migration assays, RNA-seq, phosphoproteomics, and imaging are commonly used.
What cell models are available for CXCL12 receptor research?
Knockout, point-mutation, knock-in, and overexpression models can be generated with CRISPR.
Conclusion
GO:0038147, C-X-C motif chemokine 12 receptor activity, is a central molecular function that translates CXCL12 binding into diverse cellular responses. Its dysregulation is implicated in cancer, immunodeficiency, and tumor microenvironment remodeling, making it a high-value target for research and therapy. CRISPR-based models provide powerful tools to dissect the precise roles of CXCR4, CXCR7, and downstream effectors. Continued study of this axis will inform new therapeutic strategies.
References
- 1. Cambier S et al.. 2023. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.. Cell Mol Immunol 20(3):217-251 PMID: 36725964
- 2. Lee HW et al.. 2015. Tpl2 induces castration resistant prostate cancer progression and metastasis.. Int J Cancer 136(9):2065-77 PMID: 25274482
- 3. Wani N et al.. 2014. C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.. Breast Cancer Res 16(3):R54 PMID: 24886617
- 4. Majumdar S et al.. 2018. Adaptive Immunodeficiency in WHIM Syndrome.. Int J Mol Sci 20(1) PMID: 30577453
- 5. Guo J et al.. 2022. C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 7(CXCR7) regulates epithelial-mesenchymal transition process and promotes the metastasis of esophageal cancer by activating signal transducer and activator of transcription 3 (STAT3) pathway.. Bioengineered 13(3):7425-7438 PMID: 35264069
- 6. Gao X et al.. 2018. Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.. PLoS One 13(9):e0204041 PMID: 30248140
- 7. Zhou W et al.. 2019. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.. Curr Med Chem 26(17):3026-3041 PMID: 28875842
- 8. Portella L et al.. 2021. CXCL12 Signaling in the Tumor Microenvironment.. Adv Exp Med Biol 1302:51-70 PMID: 34286441
